A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
ConditionNeurotoxicity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.
Eligibility criteria
Qualifiers
None
Disqualifiers
Ages Eligible for Study: 18 Years and above (Adult, Older Adult)
Sexes Eligible for Study: All
Patient with histologically proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center
Ability to understand and the willingness to sign a written informed consent document.
Trial design
Treatments tested in this trial
- NeurOptics® NPi®-300 Pupillometer
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov